Back to Journals » OncoTargets and Therapy » Volume 14

Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant

Authors Liu Q, Harris N, Epperla N, Andritsos LA

Received 1 December 2020

Accepted for publication 6 February 2021

Published 9 March 2021 Volume 2021:14 Pages 1797—1805


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Gaetano Romano

Qiuying Liu,1 Nicholas Harris,1 Narendranath Epperla,2 Leslie A Andritsos1,3

1Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA; 2Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; 3University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA

Correspondence: Leslie A Andritsos
University of New Mexico, 1201 Camino de Salud, Albuquerque, NM, 87102, USA
Tel +1-505-925-0405
Fax +1-505-925-0408
Email [email protected]

Abstract: Hairy cell leukemia variant (HCL-v) is a rare B-cell lymphoproliferative disorder with distinct immunophenotypic and molecular characteristics when compared to classical hairy cell leukemia (HCL-c). In contrast to the enormous progress in therapeutic options for HCL-c, HCL-v remains a therapeutic challenge due to inferior outcomes with standard chemoimmunotherapy and BCR signaling pathway inhibitors, and due to the fact that HCL-v has limited molecular therapeutic targets. In addition, because of the rarity of the disease, there is a paucity of later phase studies or multicenter trials to guide treatment decisions. In this article, we briefly review the diagnostic criteria and clinical characteristics of HCL-v and present a comprehensive overview of current therapeutic options in HCL-v.

Keywords: salvage therapy, rare lymphoid malignancies, HCL-v, HCL-c

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]